SCHEDULE: Suvretta Capital Discloses 11.9% Stake in Veradermics

Suvretta Capital Management and its affiliated funds have disclosed an 11.9% beneficial ownership stake in Veradermics, Inc., following significant investments including preferred stock conversions, IPO participation, and open market purchases.

Summary

• Suvretta Capital Management, LLC, along with Averill Master Fund, Ltd., Averill Madison Master Fund, Ltd., and Aaron Cowen (collectively, the "Reporting Persons"), beneficially own 4,168,991 shares of Veradermics, Inc. Common Stock, representing 11.9% of the class.
• The ownership stake is based on 35,077,084 shares of Common Stock outstanding as of February 4, 2026, as indicated in Veradermics' Final Prospectus.
• The Reporting Persons acquired their shares through a series of transactions, including direct purchases of Series B and Series C Preferred Stock in November 2024 and October 2025, respectively, which subsequently converted into Common Stock.
• Averill Master Fund purchased 8,299,443 shares of Series B Preferred Stock for approximately $10 million in November 2024.
• In October 2025, Averill Master Fund purchased 8,833,764 shares of Series C Preferred Stock for approximately $11.24 million, and Averill Madison Master Fund purchased 597,972 shares of Series C Preferred Stock for approximately $0.76 million.
• On January 27, 2026, a 1-for-10.067 reverse stock split occurred, and preferred shares converted into Common Stock.
• The Funds also participated in Veradermics' Initial Public Offering (IPO) on February 5, 2026, purchasing a combined 2,125,000 shares of Common Stock at $17.00 per share for a total of $36,125,000.
• Further open market purchases of Common Stock were made by the Funds in February 2026, totaling 133,080 shares by Averill Master Fund for approximately $4.94 million and 149,573 shares by Averill Madison Master Fund for approximately $5.62 million.
• The Reporting Persons hold these securities for investment purposes and may adjust their holdings based on various market and company-specific factors.
• David Friedman, M.D., a Managing Director and Senior Analyst at Suvretta Capital, was appointed to Veradermics' Board of Directors in December 2025, potentially influencing corporate activities.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal, reflecting significant institutional confidence in Veradermics, evidenced by substantial investment across multiple stages (preferred, IPO, open market) and board representation.

Positives

• A significant institutional investor, Suvretta Capital Management, has taken a substantial 11.9% stake in Veradermics, indicating strong confidence in the company's prospects.
• The investment includes participation in the company's Initial Public Offering (IPO) and subsequent open market purchases, demonstrating continued commitment.
• The appointment of David Friedman, M.D., a Managing Director and Senior Analyst at Suvretta Capital, to Veradermics' Board of Directors provides strategic oversight and alignment of interests.
• The Investors' Rights Agreement grants the Funds certain registration rights, offering potential liquidity pathways for their holdings in the future.

Risks

• The Reporting Persons may purchase additional securities or dispose of existing securities at varying times, which could introduce volatility to the stock price.
• The value of the investment is subject to the business prospects of Veradermics, broader economic conditions, and stock market conditions.
• The Lock-Up Agreements restrict the transfer of shares for 180 days after February 3, 2026, limiting the immediate liquidity for the Reporting Persons' holdings.

Future Outlook

The Reporting Persons intend to hold their securities for investment purposes and may acquire or dispose of additional securities based on ongoing assessments of Veradermics' business prospects, economic conditions, stock market conditions, and management actions. They may also engage in discussions with Veradermics' management and board, potentially offering suggestions regarding financing or other corporate activities.

Management Comments

• Aaron Cowen, Managing Member of Suvretta Capital Management, LLC, is the control person of Suvretta Capital and disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein.

Industry Context

StockSavvy.ai notes that a significant stake taken by a prominent investment manager like Suvretta Capital, especially around an IPO, often signals strong institutional confidence in the company's long-term potential within its sector. This type of investment can attract further investor interest and provide a degree of stability to the newly public company's stock.

Comparison to Industry Standards

• The 11.9% stake by Suvretta Capital is a substantial position for an institutional investor in a newly public company, often exceeding typical initial allocations seen in many IPOs, suggesting a high conviction investment.
• The appointment of a Managing Director from the investing firm to the board, as seen with David Friedman, M.D., is a common practice for significant strategic investors, aligning their interests directly with the company's governance and strategic direction, similar to what was observed with Third Point LLC's involvement with Campbell Soup Company or ValueAct Capital's engagement with Microsoft in the past.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The significant institutional investment and board representation by Suvretta Capital could be viewed positively, potentially signaling confidence and attracting further investment. The Investors' Rights Agreement provides future liquidity options for major shareholders.
• Management: The presence of a representative from a major investor on the board could lead to increased scrutiny and strategic input, potentially influencing corporate decisions and financing strategies.
• Creditors: No direct impact mentioned, but a strong institutional investor base can indirectly enhance a company's financial stability and access to capital.

Next Steps

• The Issuer has agreed to file a registration statement on Form S-1 covering the resale of a majority of Registrable Securities within 60 days of a request by holders of at least 35% of such securities, provided the aggregate offering price exceeds $20 million, starting 180 days after January 30, 2026.
• Once eligible for Form S-3, the Issuer has agreed to file an S-3 registration statement covering the resale of Registrable Securities within 45 days of a request by holders of at least 20% of such securities, provided the aggregate offering price exceeds $1 million.
• The Issuer will include Registrable Securities in any proposed registration of its own securities under the Securities Act of 1933, subject to certain limitations.

Key Dates

Recommendation

The filing indicates a significant, strategic investment by a reputable institutional firm, Suvretta Capital, including a board seat. This suggests a positive long-term outlook from a sophisticated investor. However, as a Schedule 13D, it primarily details ownership and intentions rather than financial performance. While the institutional backing is a strong positive, a 'hold' recommendation is prudent for a seasoned investor until more comprehensive financial results and strategic updates from Veradermics become available to fully assess the company's operational performance and valuation post-IPO.

Keywords

Veradermics Inc, Suvretta Capital Management, Schedule 13D, Beneficial Ownership, Common Stock, IPO, Institutional Investment, Corporate Governance, Preferred Stock Conversion, Open Market Purchases